Sumitomo’s FY2021 Sales Up 8.5% on Otsuka Pact, North America/China Growth; Chairman Tada to Retire

Sumitomo Pharma said on May 13 that its FY2021 group revenue surged 8.5% on the back of an upfront payment from Otsuka Pharmaceutical associated with their CNS alliance deal and solid growth in the North America and China business. In...read more